Literature DB >> 19489660

Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.

Nilendu Sarma1.   

Abstract

A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme. He also had a primary malignant fibrous histiocytoma of the thigh that was amputated 5 years earlier. A rash developed after 7 days of radio- and chemotherapy. It was an extensive maculopapular rash that started over the temporal area of the head and rapidly spread, sparing only the distal limbs. Radiotherapy and temozolomide were stopped on the tenth day but the rash rapidly progressed for the next 4-6 days. Following this, the spread halted and complete recovery was observed within the next 2 weeks. The peculiarity of the presentation in this case was that the brunt of the disease with severe skin denudation was localized to the surrounding areas of cranial radiotherapy. The patient was also receiving oral phenytoin, diclofenac, and parenteral dexamethasone before chemotherapy was started. These medications were continued, even after development of the skin rash, until well after full recovery from the skin lesions. After critical evaluation of disease onset, progression, and recovery, and their relationship to the introduction and withdrawal of different medicines, it appeared that either temozolomide alone or in combination with radiotherapy most probably triggered the condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19489660     DOI: 10.2165/00128071-200910040-00007

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

1.  Phenytoin- and cranial radiotherapy-induced toxic epidermal necrolysis treated with combination therapy: systemic steroid and intravenous immunoglobulin.

Authors:  E Fidan; M Fidan; F Ozdemir; H Kavgaci; F Aydin
Journal:  Med Oncol       Date:  2011-02-24       Impact factor: 3.064

2.  Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma.

Authors:  E Deluche; S Leobon; F Touraine; P Clavère
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

3.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

4.  Stevens Johnson Syndrome in a patient undergoing gynaecological brachytherapy: An association or an incident?

Authors:  Miguel Reis Ferreira; Ana Amado; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2011-04-08

5.  Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.

Authors:  Reena P Thomas; Lawrence Recht; Seema Nagpal
Journal:  Clin Pharmacol       Date:  2012-12-27

6.  Toxic epidermal necrolysis in polymedicated patient treated with radiotherapy.

Authors:  Remedios Pérez-Calderón; M Angeles Gonzalo-Garijo; Silvia Corrales-Vargas; Gloria Jiménez-Ferrera; Isabel Rodríguez-Nevado; Mario Díaz-Delgado
Journal:  Allergy Asthma Immunol Res       Date:  2014-09-19       Impact factor: 5.764

Review 7.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

8.  Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.

Authors:  Liqin Wang; Sheril Varghese; Fatima Bassir; Ying-Chin Lo; Carlos A Ortega; Sonam Shah; Kimberly G Blumenthal; Elizabeth J Phillips; Li Zhou
Journal:  Front Med (Lausanne)       Date:  2022-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.